Scarica l'app Stockscreener
12.94
0.54%
-0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$13.01
Aprire:
$13.13
Volume 24 ore:
778.36K
Relative Volume:
0.71
Capitalizzazione di mercato:
$1.07B
Reddito:
$46.02M
Utile/perdita netta:
$-70.80M
Rapporto P/E:
-7.1099
EPS:
-1.82
Flusso di cassa netto:
$-1.61M
1 W Prestazione:
-2.71%
1M Prestazione:
-18.77%
6M Prestazione:
+17.53%
1 anno Prestazione:
+105.07%
Intervallo 1D:
$12.79
$13.69
Intervallo di 1 settimana:
$12.50
$14.32
Portata 52W:
$3.91
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Nome
Eyepoint Inc
Settore
Industria
Telefono
617-926-5000
Indirizzo
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
12.94 | 1.08B | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-07 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-22 | Iniziato | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Mizuho | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2021-01-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Ripresa | Laidlaw | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
Mostra tutto
Eyepoint Inc Borsa (EYPT) Ultime notizie
EyePoint Pharmaceuticals Teases Mid-2026 DURAVYU Wet AMD Data, Starts Phase III DME Program - Yahoo Finance
EyePoint at Guggenheim Summit: Strategic Insights for 2026 By Investing.com - Investing.com Canada
EYPT: Pivotal wet AMD and DME trials advance, with DURAVYU targeting six-month dosing and strong safety - TradingView
Why is EyePoint Pharmaceuticals Inc. stock going upWall Street Watch & Free Risk Controlled Daily Trade Plans - mfd.ru
Published on: 2026-02-11 23:37:15 - mfd.ru
RBC Capital reiterates Outperform rating on EyePoint stock amid recent decline By Investing.com - Investing.com South Africa
Stocks showing market leadership: EyePoint earns 93 RS rating - MSN
RBC Capital reiterates Outperform rating on EyePoint stock amid recent decline - Investing.com Nigeria
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading 7.8% HigherHere's Why - MarketBeat
Quarterly Risk: Will EyePoint Pharmaceuticals Inc outperform tech stocksJuly 2025 Gainers & AI Driven Price Predictions - baoquankhu1.vn
EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
EyePoint, Inc.'s (NASDAQ:EYPT) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors - simplywall.st
Aug Intraday: Is ProShares Trust ProShares UltraPro Short MidCap400 still a buy after recent gainsMarket Movement Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Analysts Are Bullish on These Healthcare Stocks: EyePoint Pharmaceuticals (EYPT), BrightSpring Health Services, Inc. (BTSG) - The Globe and Mail
RSI Alert: EyePoint (EYPT) Now Oversold - Nasdaq
Mizuho reiterates Outperform rating on EyePoint stock amid share weakness By Investing.com - Investing.com South Africa
Mizuho reiterates Outperform rating on EyePoint stock amid share weakness - Investing.com
How Eyepoint Pharmaceuticals Inc. (EYPT) Affects Rotational Strategy Timing - Stock Traders Daily
Despite currently being unprofitable, EyePoint (NASDAQ:EYPT) has delivered a 195% return to shareholders over 3 years - Yahoo Finance
EyePoint, Inc. (EYPT) Stock Analysis: A Biotech With A 144% Upside Potential - DirectorsTalk Interviews
Several EyePoint Insiders Sell Shares Sending Potential Negative Signal - 富途牛牛
Federated Hermes Inc. Trims Holdings in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Winners Losers: Should I hold or sell EyePoint Pharmaceuticals Inc now2025 Market Sentiment & Safe Capital Allocation Plans - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 5.3%Here's What Happened - MarketBeat
Aug Final Week: How does E2open Parent Holdings Inc. correlate with NasdaqMarket Performance Recap & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Chipmakers Recap: Can EyePoint Pharmaceuticals Inc expand its profit marginsTrade Exit Report & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Trade Recap: What is the long term forecast for EyePoint Pharmaceuticals Inc stockWeekly Profit Summary & High Accuracy Investment Signals - baoquankhu1.vn
(EYPT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Insider Trends: What are analysts price targets for EyePoint Pharmaceuticals IncGDP Growth & Safe Entry Momentum Tips - baoquankhu1.vn
Volatility Watch: Is EyePoint Pharmaceuticals Inc stock overvalued or fairly pricedMarket Performance Recap & High Return Trade Opportunity Guides - baoquankhu1.vn
Aug Reactions: Will URTY stock go up in YEARJuly 2025 Rallies & Weekly High Momentum Picks - baoquankhu1.vn
EyePoint (EYPT) Issues Stock Options to New Employees - GuruFocus
EyePoint, Inc. (EYPT) Stock Analysis: Exploring the 127.80% Potential Upside in a Challenging Market - DirectorsTalk Interviews
EyePoint, Inc. Grants Stock Options to New Employees as Inducement Awards - Quiver Quantitative
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap UpTime to Buy? - MarketBeat
Equities Analysts Issue Forecasts for EYPT Q3 Earnings - MarketBeat
EyePoint, Inc. Provides Corporate Update and Anticipated Milestones for 2026 - VisionMonday.com
Responsive Playbooks and the EYPT Inflection - Stock Traders Daily
Can EyePoint Pharmaceuticals Inc. stock maintain growth trajectory2025 Technical Patterns & Safe Capital Growth Stock Tips - Улправда
Is EyePoint Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Weekly Recap & AI Driven Price Predictions - ulpravda.ru
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 4.6%Here's Why - MarketBeat
Will EyePoint Pharmaceuticals Inc. stock remain a Wall Street favoriteGrip and Outsole Review & road comfort picks for daily use - Улправда
EyePoint, Inc. (EYPT) Stock Analysis: Exploring the 111% Upside Potential Amidst Strategic R&D - DirectorsTalk Interviews
How sustainable is EyePoint Pharmaceuticals Inc. stock dividend payoutMarket Performance Report & Safe Entry Point Identification - ulpravda.ru
How EyePoint Pharmaceuticals Inc. stock reacts to inflationary pressuresJuly 2025 Gainers & Real-Time Volume Analysis Alerts - ulpravda.ru
Aug Ideas: Is EyePoint Pharmaceuticals Inc. stock affected by interest rate hikes2025 Year in Review & Safe Investment Capital Preservation Plans - Улправда
Is EyePoint Pharmaceuticals Inc. stock affected by interest rate hikesPortfolio Value Summary & High Conviction Buy Zone Alerts - ulpravda.ru
Will EyePoint Pharmaceuticals Inc. stock continue dividend increasesMarket Volume Report & Entry Point Confirmation Alerts - ulpravda.ru
Eyepoint Inc Azioni (EYPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):